This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:symptoms:hormonal:blood_pressure [12.28.2018] – [Concerns about the hypotensive effects of olmesartan] sallieq | home:symptoms:hormonal:blood_pressure [01.17.2019] – [see also] sallieq | ||
---|---|---|---|
Line 13: | Line 13: | ||
===== Concerns about " | ===== Concerns about " | ||
- | The NIH has created no medical standards that define low blood pressure, or a range in which low blood pressure is considered dangerous. In 2004, the NIH issued [[http:// | + | The NIH has created no medical standards that define low blood pressure, or a range in which low blood pressure is considered dangerous. In 2004, the NIH issued [[http:// |
< | < | ||
Line 69: | Line 69: | ||
=== see also === | === see also === | ||
- | [[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2346.2001.00958.x/pdf|Hypotension during endotoxemia | + | [[https://www.hindawi.com/journals/jsm/2018/ |
+ | |||
[[https:// | [[https:// | ||
Line 78: | Line 80: | ||
+ | Endotoxemia causes hypotension characterized by vasodilation and resistance to vasopressor agents. | ||
+ | |||
+ | |||
+ | Hypotension during endotoxemia in aged humans. | ||
+ | | ||
+ | |||
+ | Enhanced modulation of hypotension in endotoxemia by concomitant nitric oxide synthesis inhibition and nitric oxide scavenging. | ||
+ | (({{pubmed> | ||
===== Symptom management ===== | ===== Symptom management ===== | ||